ArticleHuman vaccines & immunotherapeutics2026
Mapping the TNFR2-targeting antibody patent landscape: Insights from macro trends to structural signatures.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological modulation of TNFR2 function has emerged as an effective strategy for modulating immune responses in cancer and inflammatory diseases. Both academic and industrial efforts have pursued therapeutic approaches targeting TNFR2, leading to a substantial accumulation of patents. Beyond documenting translational activity, these patents disclose molecular and structural design features that are often overlooked in academic literature, yet remain insufficiently integrated into systematic analyses. In this study, 3,291 TNFR2-related patents indexed in the Derwent database were first categorized by therapeutic strategy. Structural analyses were performed to characterize binding interfaces and epitope features of patented TNFR2-targeting monoclonal antibodies (mAbs) using AlphaFold3, alongside comparative analyses of complementarity-determining region (CDR) sequences to identify conserved motifs and physicochemical properties distinguishing agonists from antagonists. Results show a strategic shift from soluble TNFR2-based approaches toward receptor-targeting biologics, with mAbs now dominating. Thus, structural features of antibodies emerge as a central element for understanding TNFR2-related patent design strategies. Structural mapping classified TNFR2-targeting antibodies into five archetypal binding modes, delineating distinct agonistic and antagonistic epitope hotspots. Sequence analysis demonstrated conserved amino acid positions within CDRs, and antagonist antibodies exhibited a significantly higher frequency of acidic residues, particularly glutamate, in the CDR-H3 loop, suggesting a role for electrostatic complementarity in receptor inhibition. While this analysis relies on predicted rather than experimentally resolved structures, it delineates clear structure-function trends. It provides a forward-looking, structure-informed framework to guide the rational design and optimization of TNFR2-directed antibodies. These insights will shape the next generation of more precise and effective immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.